清肝泻火方对Graves病大鼠炎性因子及相关蛋白表达的影响
|
摘要
目的:
采用血清型小肠结肠炎耶尔森氏菌免疫纯种Wistar大鼠建立GD模型,比较清肝泻火方不同剂量之间的疗效差异,探讨清肝泻火方的组方合理性,验证GD发病与甲状腺炎症反应引起的病理损伤密不可分的假说,初步阐明GD从肝火论治的机理。为GD病辨证施治提供新思路,进一步开发新药物奠定理论基础与实验依据。
方法:
采用血清型小肠结肠炎耶尔森氏菌免疫纯种Wistar大鼠建立GD模型,再将造模后GD大鼠随机分为五组:1模型组;2中药低剂量组;3中药中剂量组;4中药高剂量组;5甲巯咪唑组以及未造模的生理对照组。分别应用清肝泻火方大、中、小剂量组和西药组干预治疗,并运用放射免疫分析法检测甲状腺激素、免疫组化法检测核因子-κB、逆转录多聚酶链法(RT-PCR)等方法检测细胞因子、用ELISA法检测血清C-反应蛋白、细胞间黏附分子和肿瘤坏死因子。
结果:
1.GD大鼠甲状腺激素的实验结果:
模型组大鼠的血清TSH明显降低,FT_3、FT_4明显升高并与正常组有显著性差异(P<0.01),提示造模成功。经过治疗后,西药组和各中药治疗组TSH、FT_3、FT_4与造模组有显著性差异(P<0.01),提示各治疗组治疗效果较好,具有明显抗甲状腺功能亢进的作用。小剂量、中剂量中药组与西药基本相当,而大剂量组明显好于其他各组,有显著性差异(P<0.01)。
2.GD大鼠血清C-反应蛋白表达的实验结果:
模型组大鼠血清CRP明显升高、与正常组相比有显著性差异(P<0.01),提示GD的发生、发展与炎症密切相关。小剂量、中剂量、大剂量中药治疗组CRP含量与模型组有显著性差异(P<0.01)。中剂量中药组与小剂量、大剂量中药组也存在显著性差异(P<0.01),中剂量组优于大剂量组和西药组。这一结果提示,中药中剂量组治疗效果较好,优于中药大剂量组和西药组。中药大、中、小剂量组的血清CRP含量变化与其相应的各组甲状腺激素水平的变化的不同步,提示CRP含量与甲状腺激素水平可能无相关性,CRP是否为GD病发生发展的独立因素还有待于进一步研究。
3.GD大鼠细胞间黏附分子(ICAM-1)表达的实验结果
模型组大鼠的血清ICAM-1含量明显升高,与正常组相比有显著性差异(P<0.01)。小剂量、中剂量、大剂量中药治疗组ICAM-1含量与造模组有显著性差异(P<0.01)。各中药治疗组之间无明显差异(P>0.05),与西药组亦无明显差异(P>0.05),提示各治疗组治疗效果无差异。
4.GD大鼠甲状腺NF-κB表达的实验结果:
模型组大鼠甲状腺上皮细胞NF-κB表达明显升高,与正常组有显著性差异(P<0.01)。病理结果显示模型组大鼠甲状腺细胞光密度显著增强,多数阳性信号同时出现于胞浆和胞核中,细胞胞浆内棕黄色颗粒堆积较多,呈片状分布。中药小剂量、中剂量、大剂量治疗组NF-κB含量与模型组有显著性差异(P<0.01)。各治疗组胞浆内棕黄色颗粒堆积较分散,呈点状分布,提示中药组各个剂量组治疗效果较明显。其大剂量中药组与小剂量、中剂量中药组存在显著性差异(P<0.01),与西药组无差异(P>0.05),大剂量组疗效优于小、中剂量组。
5.GD大鼠血清IL-6mRNA,IL-10mRNA表达的实验结果:
模型组大鼠血清IL-6mRNA表达明显升高、光带最亮,其平均光密度OD值与正常组有显著性差异(P<0.01)。各个治疗组的OD值均显著下降,与模型组有显著性差异(P<0.01),中剂量组与西药组、小、大剂量组有显著性差异(P<0.01),说明中剂量组疗效优于大剂量组和西药组。
模型组大鼠血清IL-10mRNA光密度值显著降低,与正常组相比有显著性差异(P<0.01),中药大、中、小剂量组与模型组相比有显著性差异(P<0.01),中药大剂量组与小剂量组、中剂量组、西药组之间存在显著性差异(P<0.01),中药大剂量组疗效最好。
6.GD大鼠血清TNF-α表达的实验结果
造模组大鼠血清TNF-α明显升高,与正常组有显著性差异(P<0.01),小剂量、中剂量、大剂量中药治疗组TNF-α含量与模型组有显著性差异(P<0.01)。各治疗组之间无显著性差异(P>0.05),这一结果直接证实TNF-α参与GD免疫反应过程,随着疾病的控制,其含量也显著性的降低。
结论:
1采用大鼠尾静脉注射小肠结肠炎耶尔森氏菌制作的GD模型表达出动物GD主要特征,用其进行药物及病理等方面的研究具有实用性。
2中药清肝泻火方能够改善甲状腺激素水平,具有抗甲状腺功能亢进的作用。
3 GD大鼠模型存在炎性因子和炎性蛋白的高表达,显示GD与炎症的密不可分性。
4中药清肝泻火方具有调控和改善炎性因子和炎性蛋白表达的作用。
Objective:
Graves Disease(GD) model is established by immuning Wistar rats with Y.E.to draw analogy between the curative effect of the decoction that subdue the pathogenic fire in liver in different dosage,discuss whether the composition of the decoction that subdue the pathogenic fire in liver is reasonable,verify the hypothesis that the occuring of GD is closely related to the pathological injury caused by partial inflammation in the thyroid gland and expond the mechanism of treating GD through subduing the pathogenic fire in liver.So as to find new methods for the bianzhengshizhi of GD,and lay the theoretical foundation and experimental evidence for the further development of new drugs.
Method:
Take immuned Wistar rats with Y.E.as the experimental model, then divide the rats into 5 groups randomly:1.model group;2.group of small dosage of herbal medicine;3.group of medium dosage of herbal medicine;4.group of large dosage of herbal medicine;5.group of thiamazole;treat them with small,medium,large dosage of herbal medicine and western medicine respectively.And TH is examined by RIA,NF-κB is examined by Immunohistochemistry Technique,CK is examined by RT-PCR,CRP and ICAM-1 is examined by ELISA.
Result:
1.Result of TH of the GD rats:
The Tsh of the rats in model group decreased obviously,and t he FT_3,FT_4 of the rats in model group rose significantly,and the re were obvious difference between the normal group and the mod el group,indicating that the model was successfully established (P<0.01).It was of significant difference when the group of we stern and the groups of herbal medicine were compared with the model group(P<0.01),which indicated that the curative effect was remarkable and played the role of anti-thytoglobulin.And th ere was no obvious difference between the group of western medi cine and the groups of small,medium dosage of herbal medicine(P >0.05),and the large-dosage of hebal medicine was quite differe nt.Curative effect of small-dosage,medium-dosage of hebal med icine and western medicine group was quite basic and large-dosa ge was significantly better than the other groups(p<0.01).
2.Result of CRP of the GD rats:
The CRP of the rats in model group rose obviously,which was significantly different from the model group(P<0.01),indicating that the occurance and development of GD were closely related to the inflammation.There were obvious differences between the treating groups of small,medium and large dosage of herbal medicine and the model group(P<0.01).And there were also obvious differences between the group of small,large dosage of herbal medicine and the group of mediun dosage of herbal medicine(P<0.01).The group of medium dosage of herbal medicine was more superior than the group of large dosage of herbal medicine and the western medicine(P<0.01). The result indicated that the curative effect of the group of medium dosage of herbal medicine was more remarkable than the group of large dosage of herbal medicine and the western medicine group.The fluctuation of TH of the rats in the groups of small,medium and high dosage of herbal medicine did not synchronise with the fluctuation of CRP,indicating the fluctuation of CRP beared no obvious relation to the fluctuation of TH.So,whether CRP is an independent factor of the occurrence and development of GD should be studied further more thoroughly.
3.Result of ICAM-1 of the GD rats:
The ICAM-1 of the rats in model group rose obviously,which was significantly different from the normal group(P<0.01).There were obvious differences in ICAM-1 between the treating group of small,medium,large dosage of herbal medicine and the model group(P<0.01).Apart from the above mentioned,there were no significant differences among the treating groups of herbal medicine(p>0.05),and they were also different from the western medicine group(p>0.05),indicating that the treatment groups have no different in treatment effect.
4.Result of NF-kB of the GD rats:
The NF-κB of the rats in model group rose obviously,which was significantly different from the normal group(P<0.01).The pathological result showed that the density of TEC of the rats in model group increased obviously,the majority of positive signals existed in nucleus and cytoplasm at the same time.And there was lots of brown particles in the cytoplasm,ranging in slices, indicating that there were obvious differences in NF-κB between the treating group of small,medium,large dosage of herbal medicine and the model group(P<0.01).The treatment group intracytoplasmic accumulation of brown granules scattered,suggesting the group of herbal medicine treatment in all dosage groups was more apparent. There was a significant difference between its large-dosage group and small-dosage group medicine in the dosage of herbal medicine, (P<0.01),but no difference with the western medicine(p>0.05).In treatment effect,the large-dosage group was better than the small and medium dosage group.
5.Result of IL-6mRNA,IL-10mRNA of the GD rats:
The IL-6mRNA of the rats in the model group rose obviously,with a brightest light band,and its average of OD was significantly different from the normal group(P<0.01).ODs in each treating groups fell obviously,and was significantly different from the model group(P<0.01).There were also of great difference among the group of medium dosage of herbal medicine,the group of western medicine and the group of large dosage of herbal medicine(P<0.01),indicating that the curative effect of the group of medium dosage of herbal medicine was better than the group of large dosage of herbal medicine and western medicine.
The IL-10mRNA of the rats in the model group decreased obviously, and was obviously different from the normal group(P<0.01).There were significant differences between the treating groups and the model group(P<0.01).There were significant differences between the large-dosage group and small-dosage group,medium-dosage group, the western medicine group.And the large-dosage group of herbal medicine had the best effect.
6.Result of TNF-a of the GD rats:
The TNF-αof the GD rats in the model group rose obviously, which was significantly different from the normal group(P<0.01).There existed obvious differences between the treating groups of small,medium,large dosage of herbal medicine and the model group(P<0.01).No significant difference was found in each treating group(P<0.01).There was significant difference between the treating groups and the normal group(P<0.01).This result directly verified that TNF- a took part in the immune response.With the controlling of the disease,the content of TNF-αfell obviously and its fluctuation was not synchronical with the ones of FT_3,FT_4,TSH.It indicated that TNF-αcould not be the independent factor of the cause of GD while the disease was the result of the pathogenic factor in many collaborative.
Conclusion:
1.The GD model established by injecting Y.E.into tail vain of rat shows the major character of GD in animal.This method is effective and advanced in researching of medicine and pathology.
2.The decoction that subdue pathogenic fire in liver can improve TH level,and play the role of anti-thyroid.
3.The high level of inflammatory protein and inflammatory factors in the rats in GD model group thoroughly proved that GD is closely related to inflammation.
4.The decoction of subduing pathogenic fire in liver can control and improve the condition of disorder like the inspects saying above.
采用血清型小肠结肠炎耶尔森氏菌免疫纯种Wistar大鼠建立GD模型,比较清肝泻火方不同剂量之间的疗效差异,探讨清肝泻火方的组方合理性,验证GD发病与甲状腺炎症反应引起的病理损伤密不可分的假说,初步阐明GD从肝火论治的机理。为GD病辨证施治提供新思路,进一步开发新药物奠定理论基础与实验依据。
方法:
采用血清型小肠结肠炎耶尔森氏菌免疫纯种Wistar大鼠建立GD模型,再将造模后GD大鼠随机分为五组:1模型组;2中药低剂量组;3中药中剂量组;4中药高剂量组;5甲巯咪唑组以及未造模的生理对照组。分别应用清肝泻火方大、中、小剂量组和西药组干预治疗,并运用放射免疫分析法检测甲状腺激素、免疫组化法检测核因子-κB、逆转录多聚酶链法(RT-PCR)等方法检测细胞因子、用ELISA法检测血清C-反应蛋白、细胞间黏附分子和肿瘤坏死因子。
结果:
1.GD大鼠甲状腺激素的实验结果:
模型组大鼠的血清TSH明显降低,FT_3、FT_4明显升高并与正常组有显著性差异(P<0.01),提示造模成功。经过治疗后,西药组和各中药治疗组TSH、FT_3、FT_4与造模组有显著性差异(P<0.01),提示各治疗组治疗效果较好,具有明显抗甲状腺功能亢进的作用。小剂量、中剂量中药组与西药基本相当,而大剂量组明显好于其他各组,有显著性差异(P<0.01)。
2.GD大鼠血清C-反应蛋白表达的实验结果:
模型组大鼠血清CRP明显升高、与正常组相比有显著性差异(P<0.01),提示GD的发生、发展与炎症密切相关。小剂量、中剂量、大剂量中药治疗组CRP含量与模型组有显著性差异(P<0.01)。中剂量中药组与小剂量、大剂量中药组也存在显著性差异(P<0.01),中剂量组优于大剂量组和西药组。这一结果提示,中药中剂量组治疗效果较好,优于中药大剂量组和西药组。中药大、中、小剂量组的血清CRP含量变化与其相应的各组甲状腺激素水平的变化的不同步,提示CRP含量与甲状腺激素水平可能无相关性,CRP是否为GD病发生发展的独立因素还有待于进一步研究。
3.GD大鼠细胞间黏附分子(ICAM-1)表达的实验结果
模型组大鼠的血清ICAM-1含量明显升高,与正常组相比有显著性差异(P<0.01)。小剂量、中剂量、大剂量中药治疗组ICAM-1含量与造模组有显著性差异(P<0.01)。各中药治疗组之间无明显差异(P>0.05),与西药组亦无明显差异(P>0.05),提示各治疗组治疗效果无差异。
4.GD大鼠甲状腺NF-κB表达的实验结果:
模型组大鼠甲状腺上皮细胞NF-κB表达明显升高,与正常组有显著性差异(P<0.01)。病理结果显示模型组大鼠甲状腺细胞光密度显著增强,多数阳性信号同时出现于胞浆和胞核中,细胞胞浆内棕黄色颗粒堆积较多,呈片状分布。中药小剂量、中剂量、大剂量治疗组NF-κB含量与模型组有显著性差异(P<0.01)。各治疗组胞浆内棕黄色颗粒堆积较分散,呈点状分布,提示中药组各个剂量组治疗效果较明显。其大剂量中药组与小剂量、中剂量中药组存在显著性差异(P<0.01),与西药组无差异(P>0.05),大剂量组疗效优于小、中剂量组。
5.GD大鼠血清IL-6mRNA,IL-10mRNA表达的实验结果:
模型组大鼠血清IL-6mRNA表达明显升高、光带最亮,其平均光密度OD值与正常组有显著性差异(P<0.01)。各个治疗组的OD值均显著下降,与模型组有显著性差异(P<0.01),中剂量组与西药组、小、大剂量组有显著性差异(P<0.01),说明中剂量组疗效优于大剂量组和西药组。
模型组大鼠血清IL-10mRNA光密度值显著降低,与正常组相比有显著性差异(P<0.01),中药大、中、小剂量组与模型组相比有显著性差异(P<0.01),中药大剂量组与小剂量组、中剂量组、西药组之间存在显著性差异(P<0.01),中药大剂量组疗效最好。
6.GD大鼠血清TNF-α表达的实验结果
造模组大鼠血清TNF-α明显升高,与正常组有显著性差异(P<0.01),小剂量、中剂量、大剂量中药治疗组TNF-α含量与模型组有显著性差异(P<0.01)。各治疗组之间无显著性差异(P>0.05),这一结果直接证实TNF-α参与GD免疫反应过程,随着疾病的控制,其含量也显著性的降低。
结论:
1采用大鼠尾静脉注射小肠结肠炎耶尔森氏菌制作的GD模型表达出动物GD主要特征,用其进行药物及病理等方面的研究具有实用性。
2中药清肝泻火方能够改善甲状腺激素水平,具有抗甲状腺功能亢进的作用。
3 GD大鼠模型存在炎性因子和炎性蛋白的高表达,显示GD与炎症的密不可分性。
4中药清肝泻火方具有调控和改善炎性因子和炎性蛋白表达的作用。
Objective:
Graves Disease(GD) model is established by immuning Wistar rats with Y.E.to draw analogy between the curative effect of the decoction that subdue the pathogenic fire in liver in different dosage,discuss whether the composition of the decoction that subdue the pathogenic fire in liver is reasonable,verify the hypothesis that the occuring of GD is closely related to the pathological injury caused by partial inflammation in the thyroid gland and expond the mechanism of treating GD through subduing the pathogenic fire in liver.So as to find new methods for the bianzhengshizhi of GD,and lay the theoretical foundation and experimental evidence for the further development of new drugs.
Method:
Take immuned Wistar rats with Y.E.as the experimental model, then divide the rats into 5 groups randomly:1.model group;2.group of small dosage of herbal medicine;3.group of medium dosage of herbal medicine;4.group of large dosage of herbal medicine;5.group of thiamazole;treat them with small,medium,large dosage of herbal medicine and western medicine respectively.And TH is examined by RIA,NF-κB is examined by Immunohistochemistry Technique,CK is examined by RT-PCR,CRP and ICAM-1 is examined by ELISA.
Result:
1.Result of TH of the GD rats:
The Tsh of the rats in model group decreased obviously,and t he FT_3,FT_4 of the rats in model group rose significantly,and the re were obvious difference between the normal group and the mod el group,indicating that the model was successfully established (P<0.01).It was of significant difference when the group of we stern and the groups of herbal medicine were compared with the model group(P<0.01),which indicated that the curative effect was remarkable and played the role of anti-thytoglobulin.And th ere was no obvious difference between the group of western medi cine and the groups of small,medium dosage of herbal medicine(P >0.05),and the large-dosage of hebal medicine was quite differe nt.Curative effect of small-dosage,medium-dosage of hebal med icine and western medicine group was quite basic and large-dosa ge was significantly better than the other groups(p<0.01).
2.Result of CRP of the GD rats:
The CRP of the rats in model group rose obviously,which was significantly different from the model group(P<0.01),indicating that the occurance and development of GD were closely related to the inflammation.There were obvious differences between the treating groups of small,medium and large dosage of herbal medicine and the model group(P<0.01).And there were also obvious differences between the group of small,large dosage of herbal medicine and the group of mediun dosage of herbal medicine(P<0.01).The group of medium dosage of herbal medicine was more superior than the group of large dosage of herbal medicine and the western medicine(P<0.01). The result indicated that the curative effect of the group of medium dosage of herbal medicine was more remarkable than the group of large dosage of herbal medicine and the western medicine group.The fluctuation of TH of the rats in the groups of small,medium and high dosage of herbal medicine did not synchronise with the fluctuation of CRP,indicating the fluctuation of CRP beared no obvious relation to the fluctuation of TH.So,whether CRP is an independent factor of the occurrence and development of GD should be studied further more thoroughly.
3.Result of ICAM-1 of the GD rats:
The ICAM-1 of the rats in model group rose obviously,which was significantly different from the normal group(P<0.01).There were obvious differences in ICAM-1 between the treating group of small,medium,large dosage of herbal medicine and the model group(P<0.01).Apart from the above mentioned,there were no significant differences among the treating groups of herbal medicine(p>0.05),and they were also different from the western medicine group(p>0.05),indicating that the treatment groups have no different in treatment effect.
4.Result of NF-kB of the GD rats:
The NF-κB of the rats in model group rose obviously,which was significantly different from the normal group(P<0.01).The pathological result showed that the density of TEC of the rats in model group increased obviously,the majority of positive signals existed in nucleus and cytoplasm at the same time.And there was lots of brown particles in the cytoplasm,ranging in slices, indicating that there were obvious differences in NF-κB between the treating group of small,medium,large dosage of herbal medicine and the model group(P<0.01).The treatment group intracytoplasmic accumulation of brown granules scattered,suggesting the group of herbal medicine treatment in all dosage groups was more apparent. There was a significant difference between its large-dosage group and small-dosage group medicine in the dosage of herbal medicine, (P<0.01),but no difference with the western medicine(p>0.05).In treatment effect,the large-dosage group was better than the small and medium dosage group.
5.Result of IL-6mRNA,IL-10mRNA of the GD rats:
The IL-6mRNA of the rats in the model group rose obviously,with a brightest light band,and its average of OD was significantly different from the normal group(P<0.01).ODs in each treating groups fell obviously,and was significantly different from the model group(P<0.01).There were also of great difference among the group of medium dosage of herbal medicine,the group of western medicine and the group of large dosage of herbal medicine(P<0.01),indicating that the curative effect of the group of medium dosage of herbal medicine was better than the group of large dosage of herbal medicine and western medicine.
The IL-10mRNA of the rats in the model group decreased obviously, and was obviously different from the normal group(P<0.01).There were significant differences between the treating groups and the model group(P<0.01).There were significant differences between the large-dosage group and small-dosage group,medium-dosage group, the western medicine group.And the large-dosage group of herbal medicine had the best effect.
6.Result of TNF-a of the GD rats:
The TNF-αof the GD rats in the model group rose obviously, which was significantly different from the normal group(P<0.01).There existed obvious differences between the treating groups of small,medium,large dosage of herbal medicine and the model group(P<0.01).No significant difference was found in each treating group(P<0.01).There was significant difference between the treating groups and the normal group(P<0.01).This result directly verified that TNF- a took part in the immune response.With the controlling of the disease,the content of TNF-αfell obviously and its fluctuation was not synchronical with the ones of FT_3,FT_4,TSH.It indicated that TNF-αcould not be the independent factor of the cause of GD while the disease was the result of the pathogenic factor in many collaborative.
Conclusion:
1.The GD model established by injecting Y.E.into tail vain of rat shows the major character of GD in animal.This method is effective and advanced in researching of medicine and pathology.
2.The decoction that subdue pathogenic fire in liver can improve TH level,and play the role of anti-thyroid.
3.The high level of inflammatory protein and inflammatory factors in the rats in GD model group thoroughly proved that GD is closely related to inflammation.
4.The decoction of subduing pathogenic fire in liver can control and improve the condition of disorder like the inspects saying above.
引文
[1]张木勋,吴亚群主编.甲状腺疾病诊疗学[M].北京:中国医药科技出版社,2006,190.
[2]陈如泉.甲状腺疾病的中西医诊断与治疗[M].北京:中国医药科技出版社,2001,218.
[3]白耀.甲状腺病学—基础与临床[M].北京:科学技术文献出版社,2003,244.
[1]秦川.医学实验动物学[M].人民卫生出版社,2008,415.
[2]陈奇.新编实验中药药理学[M].北京:北京科学技术出版社,1997,240.
[3]张家庆,赵明.滋阴、助阳药对“高甲”低甲”大鼠模型肝细胞核甲状腺激素受体的影响[J].中西医结合杂志,1991,11(2):105-06.
[4]Lidman K,Eriksson U,Fagraeus A,et al.Antibodies against thyroid cells in Yersinia enterocolitica infect ion[J].Lancet,1974,2:1449.
[5]梁敏,张阅珍,包幼迪,等.Graves病病因与耶尔森氏菌免疫反应的关系[J].中华内分泌代谢杂志,1995,11(3):136.
[6]陈春荣.小肠结肠炎耶尔森氏菌致Graves病作用的实验研究[J].中华内分泌代谢杂志,1998,14(3):159.
[7]赵家军,高聆,孔磊,等.Graves病患者与肠道细菌感染的关系及抗生素的应用[J].山东医药,1999,39(6):7.
[8]Takuno H,Sakata S,Miura K.Antibodies to Yersinia enteroco litica serotype 3 in autoimmune thyroid diseases[J].Endocrinol Jpn,1990,37(4):489-500.
[9]周亚娜.复方甲亢片对实验性GD大鼠白细胞保护作用的实验研究[D].湖北中医学院,2005.
[10]王庆浩.中药对免疫性Graves病大鼠的作用及其作用机理的实验研究[D].湖北中医学院,2002.
[11]吴凤霞,闾树河,张俊玲,等.甲状腺疾病中西医诊疗学[M].北京:中国中医药出版社,2001,14-15.
[12]施秉银主译.基础与临床内分泌学[M].西安:世界图书出版公司,2001,205.
[13]Carasco N.Iodide transport in the thyroid gland[J].Bioc him Biophys Acta,1993,1154:1165.
[14]Ryu Ky,senokozlieff ME,Samnik PA,et al.Developme nt of reverse transcription-competitive polymerase chain rea ction method to quantitate the expression levels of human s odium iodide symporter[J].Thyroid,1999,9:405-409.
[15]Ajjan RA,Watson PF,Findlay C,et al.The sodium iodide symporter gene and its regulation by cytokines found in autoimmunity[J].J Endocrinol,1998,158:351-358.
[16]Oyttersport N,Pelgrims N,Carrasco N,et al.Moderate doses of iodide in vivo inhibit cell proliferation and expression of thyroperoxidase and Nasymporter mRNAs in dog thyroid [J].Mol cell Endocrinol,1997,131:195-203.
[17]陈如泉.甲状腺疾病的中西医诊断与治疗[M].北京:中国医药科技出版社,2001,100-103.
[1]DiGiunfilippo G,Souecito A,et al,C-reactive protein after first ever is chemic stroke[J].Stroke,2000,31.
[2]魏有仁.C-反应蛋白:方法学与应用的进展[J].当代医学,2001,7(10):27-30.
[3]白耀.甲状腺病学—基础与临床[M].北京:科技技术文献出版社2003,146.
[4]Pranhan AD,ManonJE,Rifai N,et al.C-reactive protein,interleukin 6,and risk of developing type2 diabetes mellitus[J].J AMA,2001,286(3):327-334.
[1]De Bellis A,Di Martino S,Fiordelisi F,et al.Soluble intercellular adhesion molecule-1,(sICAM-1) Concentrations in Graves' disease patients followed up for development of ophthalmopathy[J].J Clin Endocrinol Metab 1998;83(4):1222-1225.
[2]李盈,徐海霞.外周细胞间黏附分子1水平与Graves病的相关性[J].中国组织工程研究与临床康复,2007,11:9383-9384.
[3]Hoermann R,Spitzweg C.Poertl S,et al.Regulation of intercel lular adhesion molecule-lexpression in human thyroid cells in v itro and human thyroid tissue transplanted to thenude mouse in vivo role of Graves' immunoglobulins and human thyrolropin rec eptor[J].J Clin Endocrinol,1997,82:2048.
[4]孟凤荃.细胞间黏附分子-1在Graves病免疫发病机制中的作用[J].国外医学免疫学分册,2001,24(2):96-99.
[5]De Bellis A,Di Martino S,Fiordelisi F,et al.Soluble intercellular adhesion molecule-1,(sICAM-1) Concentrations in Graves' disease patients followed up for development o f ophthalmopathy[J].J Clin Endocrinol Metab 1998,83(4):1222-1 225.
[6]Fukazawa H,Yoshida ICaise N,et al.Intercellular adhesion m olecule-1(ICAM-1) in the sera of patients with Graves' disease:Correlation with disease activity and treatment status[J].Thyro id,1995,5(5):373-377.
[7]Arreaza G.Expression of intercellular adhesion molecule-lonhuman thyroid cells from patients with autoimmune thyroid di sease:study of thyroid xenografts in nude and severe combined immu nodeficient mice and treatment with FK-506[J].J Clin End ocrinol Metab,1995,80:3724.
[8]Ishikawa N.Expression of adhesion molecules on infiltrating T cells in thyroid glands from patients with Graves' disease.C linEx p Immunol,1993,94:363.
[9]Marazuela M.Adhesion molecules from the LFA-1/ ICAM-1,3 and VLA-4/ VCAM-1 pathways on Tlymphocytes andvascular endo th elium in Graves ' and Hashimoto' s thyroidglands[J].Eur J I mmunol,1994,24:2483.
[10]Balazs C,Kiss E.Soluble intercellular adhesion molecule-1(s ICAM-1) in Graves' disease[J].Acta Microbiol Immunol Hung,1994,41:451-456.
[11]张丽,王德风,王德全.国外医学内分泌学分册,1999,(2):15-16.
[12]Metcalfe RA,Tandon N,Tamatani T,et al.Adhesion molecule mao no Clonal Antibodies inhibit experimental autoimmune thyroiditi s[J].Immunology,1993,80:493-497.
[1]Sen R Baltinore D.Muliple nuclear factors interact with the inmunoglobulin enhancer sequence cell[J].1986,46(5):705.
[2]Grey ST,Arvelo MB,Hasenkamp W,Bach FH,Ferran C.A20inhibits cytokine-induced apoptosis and nuclear factor kappaB-dependent geneactivation in islets[J].J Exp Med,1999,190(8):1135-1146.
[3]Jue DM,Jeon KI,Jeong JY Nuclear factor kappaB(NF-kappaB)pathway as a therapeutic target in rheumatoid arthritis [J].J Korean Med Scil999,14(3):231-238.
[4]Hilliard B,Samoilova EB,Liu TS,Rostami A,Chen Y Experimental autoimmune encephalomyelitis in NF-kappa B-deficient mice:roles of NF-kappa B in the activation and differentiation of autoreactive T cells[J].Jimmunol,1999,163(5):2937-2943.
[5]Burgos P,Metz C,Bull P,Pincheira R,Massardo L,Errazuriz C,Bono MR,Jacobelli S,Gonzalez A.Increased expression of c-rel,from the NF-kappaB/Rel family,in T cells from patients with systemic lupusery thematosus.J Rheumatol 2000,27(1):116-27.
[6]Altavilla D,Saitta A,Squadrito G,et al.Evidence for a role of nuclear factor2kappa B in acute hypovolemic hemorrhagic shock.[J].Surgery,2002,131:50-8.
[7]Altavilla D,Saitta A,Guarini S,et al.Oxidatice stress causes nu2clear factor2kappa B activation in acute hypovolemic hemorrhagicshock[J].Free Radic BiolMed,2001,30:1055-1066.
[8]GroveM,PlumbM.C/EBP,NF2kappa B,and c2Ets familymembers and transcriptional regulation of the cell2specific and induciblemacrophage inflammatory protein 1 alpha immediate[J].Mol CellBiol,1993,13:5276-5289.
[9]夏丽娟,陈飞虎.核因子-κB的分子生物学特性及其在炎性分子反应的作用[J].安徽医药,2005,9(3):162-164.
[10]闵迅,陈代雄,王永伦等.NF-κB在Graves病免疫病理机制中的意义[J].中国病理生理杂志,2009,25(3):536-540.
[11]赵建东、王延君、孔维佳.核因子-κB及ICAM-1 mRNA在变应性鼻炎鼻黏膜中的表达[J].临床耳鼻咽喉头颈外科杂志,2008,22(2):57-60.
[1]程磊,刘继祥.血清IL-2和IL-6及TNF-α检测在甲亢病中的临床应用[J].现代医药卫生,2005,21:3288.
[2]Bartalena L,Brogioni S,Grasso L,Mart ino E.Interleukin-6And thvroid[J].Eur J Enaocrinol,1995,132(4):386-393.
[3]Corrales JJ,Orfao A,Lopez A,et al.Analysis of IL-2 and IL-6binding to peripheral blood lymphocytes in Graves disease:relationship with disease activity[J].Cytometry,1997,15:30(3):118-123.
[4]Simons PJ,Delemarre F6,Drexhage HA.Antigen-presenting dendritic cell sas regulators of the growth of thyrocytes:a role of interleukin-1 beta and interleukin-6[J].Endocrinology,1998,139(7):3148-3156.
[5]Gi rvent M,Maestro S,Hernandez R,et al.Euthyroid Sick syndrome.a ssociated endocrine abnormalities.and outcome in elderly patient s undergoing emergencyoperation[J].Surgery,1998May,123(5):560-567.
[6]Aust G,Schbaum WA.Expression of cytokines in the thyroida hyrocytes as potentent iaicytokineproducers[J].Exp C1 in endo crin Diabetes,1996;104:46-50.
[7]Wat son PF,Pickerill AP,Davies et al.Semi-quantitative analysi-s of interleukin-1 alpha.interleukin-6 and interleukin -smRNA expres sion human thyrocytes[J].J M01 Endocrinol.1995,15(1):11-21.
[8]Yamazaki K,Yamada E,Kanaji Y,et al.Interleukin-6(IL-)inhibit Sthyroidfunction in 1,he plesence of soluble 1L-6 receptor in cultured human thyroid foilicles[J].Endocrinology,1996,137(11):4857-4863.
[9]张致丹.Graves病患者血清IL-6和IFN含量变化与临床意义[J].中国误诊学杂志,2009,9(7):1535.
[10]哈丽亚·哈力木别克,茹仙古丽·吾买尔,巴雅.Graves病患者血清IL-2、IL-6及TNF的变化[J].中国误诊学杂志,2009,9(6):1303-1304.
[11]王小宁,余江毅,顾志峰.温肾方对EAT模型甲状腺组织IL-6β表达影响的实验研究[J].江苏中医药2005,26(12):59-61.
[12]董吉祥,谢莹,汪寅,等.Graves病患者外周血IL-6.TNF-水平表达的变化及意义[J].中国免疫学杂志2006,(22):378-380.
[13]李宏.儿童AITD患者血清IL-12、IL-10在疾病不同阶段的观察[D].天津医科大学,2006
[14]Onstant SL-Bottomlv L induction of,Th_1 and Th_2 CO_4~+T Cell response the alternative approaches[J]Ann lieⅡ Immunol.1997,15,297-322.
[15]Xu WD,Fireste in GS,Taetle R,et al Cytokines in chronic in flammatory arthritis Ⅱ,granu locytes-macrophage colony stim ulating factor in rheum atoid synovial effusions[J].J G in In vest,1989,83:876-882.
[16]Takeoka K,Watanabe M,Mat suzuka F,et al.Increase of seru m interleukin-10 in intractable Graves disease[J].Thyroid.2004Mar 14(3):201-205.
[17]Wat son PF,Pickeri 11 AP,Davies R,et al.Analysis of cytokine gene expression in Graves' disease and multinodular goiter[J].J Clin Endocrinol Metab.1994 Aug,79(2):355～360.
[18]Al-Humaidi MA.SeI.um cytokines levels in Graves,disease.J Saudi Med[J].2000,21(7):539～644.
[1]Jones B M,kwok C C,Kung AW.Effect of radioact ive iodine therapy on eytokine production in Graves disease;transient increase in IL-4 IL-6 IL-10 and tumor necreasees in interferor gamma production [J].J Clin Endocrionlm Metab,1999,84(11):4106.
[2]Salvi M,pedrazzoni M,Girasole G,et al Serum concentra tions of proinflammatory cytokines in Graves'disease effect of treatment thyroid function ophthaln opathy and cigarette smokin g[J].Eur Endor crino J 2000,143(2):197-202.
[3]Liao YF,Wang BJ,Cheng HT,Kuo LH,Wolfe MS.Tumor necrosis factor-alpha,interleukin-lbeta,and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway[J].J.Biol.Chem.2004;279(47),49523-49532.
[4]Zhen Q H,Ahney E R Detection of vivo productin of turner Necros is factor alpha hY human thyroid epithelial cells [J]lmmunology,1992,75:456-462.
[5]段宇.甲状腺组织表达细胞因子IL-6 TNF-α mRNA基因的研究[J]南京医利大学学报,2000,20:91-93.
[6]Eugenin EA,Branes MC,Berman JW,Saez JC.TNF-αlpha plus IFN-gamma induce connexin43 expression and formation of gap junctions between human monocytes/macrophages that enhance physiological responses[J].J.Immunol.2003;170(3),1320-1328.
[1]白耀,主编.甲状腺病学—基础与临床[M].北京:科技技术文献出版社,2003,146.
[2]张木勋,吴亚群[M].甲状腺疾病诊疗学[M].北京:中国医药科技出版社2006,191-192.
[3]刘泽林.王玉磷.李路.等.Graves病患者血中细胞因子的变化[J].暨南大学学报,2007,28(2):176-178.
[4]Wakelknnp M,Gerdngn N van derM eerjW,et al Both Th_1 and Th_2-derived cvtok ines in Serum are elevated in Graves ophthalmopathyl[J].Clinexp lnmunol 2000,121(3):453-457.
[5]廖二元,超楚生.内分泌学[M].北京:人民卫生出版社,2001,664-693.
[6]倪晓燕.HLA等位基因多态性与自身免疫性甲状腺病[J].《国外医学》内分泌学分册,1998,18(3):113-116.
[7]Ishikawa N.Expression of adhesion molecules on infiltrating Tcells in thyroid glands from patients with Graves' disease[J].ClinExp Immunol,1993,94:363.
[8]OPAL S M.WHERRY J C.GRINT P.Interleukin-10;potential benefits and possible risk in clinical infection diseases[J].Clin Infect Dis.1998,27(6):1495-1507.
[9]BOGDAN C,PAIK J,VODOVOTZ Y.et al.Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10[J].J Biol CHEN,1992,267(32):301-308.
[10]RONCAROLO M G.BACCHETA R.BORDIGNON C,et al.Type 1 T-regulatory cells[J].Immunol Rev,2001,182:68-79.
[11]JENKINS JK,MALYAKM,ARENDWP.The effects of interleukin-10on interleukin-1 receptor antagonist and interleul:in-1 beta production in human monocytes and neutrophils[J].Lymphokine Cytokine Res,1994,13(1);47-54.
[12]钟永亮,唐荣德,肝主疏泄与甲亢病机关系初探[J].湖南中医学院学报,1994,14(3):14-16.
[13]张安玲,肝火的形成致病机制及证治规律探微[J].中医药学刊,2002,20(1):70-71.
[14]居建英,居建玲,试论肝火证[J].天津中医学院学报,2002,19(4):6.
[15]崔向阳。中医肝火证与A型性格关系探讨[J].空军总医院学报。1989.5(3):154～155.
[16]蒋岩,尹建豪.夏枯草对动物胸腺、脾脏和肾上腺的影响[J].甘肃医药,1988,7(4):4.
[17]郑昱,乔成栋,苑伟等.夏枯草胶囊对溃疡性结肠炎大鼠外周血T 淋巴细胞亚群表达的影响[J].中国中西医结合消化杂志,2004,12(1):10.
[18]马德恩,王竹梅.夏枯草的抗炎作用及对免疫器官影响的研究[J].山西医药杂志,1983,3(2):51-52.
[19]杨坤.夏枯草口服液在不同甲状腺功能状态甲状腺肿大患者中的应用[J].中国中西医结合杂志2007,27(1):37-39.
[20]王钢力,陈德帽,赵淑杰.栀子属植物化学成分研究进展[J].中国中药杂志.1996,21(2):67-67.
[21]姚全胜,周国林,朱延勤等.栀子抗炎、治疗软组织损伤有效部位的筛选研究[J].中国中药杂志,1991,16(8):486-486.
[22]Kimura Y,et al.J Elhnoyharrnacol,1997,57(1):63.
[23]蔡仙德、穆维同.黄芩苷对小鼠细胞免疫功能的影响[J].南京铁道医学院学报,1994,13(2):65-68.
[24]王新慧,蔡仙德.黄芩苷对小鼠细胞免疫粘附功能的促进作用[J].中国实验临床免疫学杂志.1992,4(3):41-43.
[25]中华本草[M].上海科技出版社.1999,218.
[26]何金森.甲亢虚火旺证与气阴两虚证的初步探讨[J].1983,14(9):67.
[27]Meyerson LR et al.Neurochesn.Ras 1978,11:239.
1.李富生主编.常见病中医临床治疗进展[M].中国中医药出版社.1991.
2.王洪泉,徐灿冲,王蕾.程益春教授治疗甲亢临证经验选粹[J].2007,17(3)162.
3.姜家全,徐灿坤,韩吉淼 辨证治疗甲状腺功能亢进症的思路与方法[J].实用中医内科杂志,2003,17(6):279.
4.陈继东,程健高.甲状腺机能亢进症从肝论治辨析[J].湖北中医杂志,2007,29(2):18.
5.杨庆云.甲亢中医治疗近况[J].四川中医.1988,(8):44.
6.王开云.安徽中医临床杂志[J].2000,12(3):182.
7.简任佑.甲状腺功能亢进症中医辨证的初步研究[D].广州中医药大学.2002.
8.安平,梁雪.毒性弥漫性甲状腺肿研究进展[J].中医药信息,2001,21(4):17-19.
9.郑献敏.甲亢(瘿气)临床辨证分型规律的研究[D].广州中医药大学.2006.
10.郭宝荣,冯建华,张娟.愈瘿片治疗甲状腺功能亢进症的临床研究[J].山东中医药大学学报,2000,24(2):97-100.
11.向楠,周亚娜.从毒论治甲状腺机能亢进症[J].湖北中医杂志,2005.27(6):5-8.
12.郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002,226-233.
13.曹国蓉.甲状腺机能亢进症的辩证论治[J].中医杂志,1996,(6):5.
14.李景顺.浅谈中医对甲亢的辨证施治[J].辽宁中医杂志,1981,(3):28.
15.金舒白.针灸治疗甲状腺机能亢进症的经验介绍[J].中国针灸,1982,(1):14.
16.陈建军.甲状腺机能亢进症的中医分型探论.全国第四届中医甲状腺疾病学术会议论文集.
17 余惠民.从肝论治甲状腺机能亢进症[J].广西中医药,1986,(5):23.
18.杨树先,王延山.甲亢的中医辨证施治[J].中国社区医师杂志,2001,12(12):27.
19.成肇智,刘琼,傅蔷.毒性弥漫性甲状腺肿分期辨治[J].中医药通报,2003,2(2):67-68.
20.张志荭,张传平.疏肝消瘿汤治疗甲状腺功能亢进32例[J].实用中医药杂志,2001,17(9):26.
21.洪志豪.夏玄平肝汤治疗甲状腺机能亢进24例[J].四川中医,2000,18(7):19.
22.赵文学.玉液汤治疗甲亢42例[J].北京中医,1999,24(6):24.
23.李以稳.中西医结合治疗甲亢58例疗效观察.江苏中医2005,(5):17.
24.王科成,刘冬岩,贾义呈,等.三黄抑亢胶囊辅以小剂量他巴唑治疗Graves病的疗效观察[J].中医杂志,1999,40(5):290.
25.杨洪,胡建兵,任卫东中药甲亢舒与131Ⅰ联合治疗甲亢临床观察[J].实用中西医结合临床,2003,3(2):13.
26.龙炎.中西医结合治疗甲状腺机能亢进症50例疗效观察[J].湖南中医药导报,2001,7(9):458.
27.林兰,李鸣摘,刘喜明,等.中药甲亢宁治疗阴虚阳亢型甲状腺功能亢进症的临床研究[J].中国中西医结合杂志,1999,19(3):144-146.
28.梁九根,蒋宁一,吕斌,等.甲亢舒配合~(131)碘治疗甲状腺机能亢进症的临床观察[J].中国中西医结合杂志,2000,20(10):774-774.
29.陈如泉主编.甲状腺疾病中西医诊断与治疗.[M].北京:中国医药科技出版社,2001
30.王立琴,陈金锭,张其兰.外敷消瘿膏治疗甲状腺肿临床观察及实验初步研究[J].中医杂志,1993,34(3):153.
31.黄柳和.挑筋割脂埋线疗法治疗甲亢[J].中国针灸,1995,28(1).
32.孙克兴,庞烟,魏建子,等.针药结合治疗Graves病眼征的临床观察[J].上海针灸杂志,2000,19(3):5.
[2]陈如泉.甲状腺疾病的中西医诊断与治疗[M].北京:中国医药科技出版社,2001,218.
[3]白耀.甲状腺病学—基础与临床[M].北京:科学技术文献出版社,2003,244.
[1]秦川.医学实验动物学[M].人民卫生出版社,2008,415.
[2]陈奇.新编实验中药药理学[M].北京:北京科学技术出版社,1997,240.
[3]张家庆,赵明.滋阴、助阳药对“高甲”低甲”大鼠模型肝细胞核甲状腺激素受体的影响[J].中西医结合杂志,1991,11(2):105-06.
[4]Lidman K,Eriksson U,Fagraeus A,et al.Antibodies against thyroid cells in Yersinia enterocolitica infect ion[J].Lancet,1974,2:1449.
[5]梁敏,张阅珍,包幼迪,等.Graves病病因与耶尔森氏菌免疫反应的关系[J].中华内分泌代谢杂志,1995,11(3):136.
[6]陈春荣.小肠结肠炎耶尔森氏菌致Graves病作用的实验研究[J].中华内分泌代谢杂志,1998,14(3):159.
[7]赵家军,高聆,孔磊,等.Graves病患者与肠道细菌感染的关系及抗生素的应用[J].山东医药,1999,39(6):7.
[8]Takuno H,Sakata S,Miura K.Antibodies to Yersinia enteroco litica serotype 3 in autoimmune thyroid diseases[J].Endocrinol Jpn,1990,37(4):489-500.
[9]周亚娜.复方甲亢片对实验性GD大鼠白细胞保护作用的实验研究[D].湖北中医学院,2005.
[10]王庆浩.中药对免疫性Graves病大鼠的作用及其作用机理的实验研究[D].湖北中医学院,2002.
[11]吴凤霞,闾树河,张俊玲,等.甲状腺疾病中西医诊疗学[M].北京:中国中医药出版社,2001,14-15.
[12]施秉银主译.基础与临床内分泌学[M].西安:世界图书出版公司,2001,205.
[13]Carasco N.Iodide transport in the thyroid gland[J].Bioc him Biophys Acta,1993,1154:1165.
[14]Ryu Ky,senokozlieff ME,Samnik PA,et al.Developme nt of reverse transcription-competitive polymerase chain rea ction method to quantitate the expression levels of human s odium iodide symporter[J].Thyroid,1999,9:405-409.
[15]Ajjan RA,Watson PF,Findlay C,et al.The sodium iodide symporter gene and its regulation by cytokines found in autoimmunity[J].J Endocrinol,1998,158:351-358.
[16]Oyttersport N,Pelgrims N,Carrasco N,et al.Moderate doses of iodide in vivo inhibit cell proliferation and expression of thyroperoxidase and Nasymporter mRNAs in dog thyroid [J].Mol cell Endocrinol,1997,131:195-203.
[17]陈如泉.甲状腺疾病的中西医诊断与治疗[M].北京:中国医药科技出版社,2001,100-103.
[1]DiGiunfilippo G,Souecito A,et al,C-reactive protein after first ever is chemic stroke[J].Stroke,2000,31.
[2]魏有仁.C-反应蛋白:方法学与应用的进展[J].当代医学,2001,7(10):27-30.
[3]白耀.甲状腺病学—基础与临床[M].北京:科技技术文献出版社2003,146.
[4]Pranhan AD,ManonJE,Rifai N,et al.C-reactive protein,interleukin 6,and risk of developing type2 diabetes mellitus[J].J AMA,2001,286(3):327-334.
[1]De Bellis A,Di Martino S,Fiordelisi F,et al.Soluble intercellular adhesion molecule-1,(sICAM-1) Concentrations in Graves' disease patients followed up for development of ophthalmopathy[J].J Clin Endocrinol Metab 1998;83(4):1222-1225.
[2]李盈,徐海霞.外周细胞间黏附分子1水平与Graves病的相关性[J].中国组织工程研究与临床康复,2007,11:9383-9384.
[3]Hoermann R,Spitzweg C.Poertl S,et al.Regulation of intercel lular adhesion molecule-lexpression in human thyroid cells in v itro and human thyroid tissue transplanted to thenude mouse in vivo role of Graves' immunoglobulins and human thyrolropin rec eptor[J].J Clin Endocrinol,1997,82:2048.
[4]孟凤荃.细胞间黏附分子-1在Graves病免疫发病机制中的作用[J].国外医学免疫学分册,2001,24(2):96-99.
[5]De Bellis A,Di Martino S,Fiordelisi F,et al.Soluble intercellular adhesion molecule-1,(sICAM-1) Concentrations in Graves' disease patients followed up for development o f ophthalmopathy[J].J Clin Endocrinol Metab 1998,83(4):1222-1 225.
[6]Fukazawa H,Yoshida ICaise N,et al.Intercellular adhesion m olecule-1(ICAM-1) in the sera of patients with Graves' disease:Correlation with disease activity and treatment status[J].Thyro id,1995,5(5):373-377.
[7]Arreaza G.Expression of intercellular adhesion molecule-lonhuman thyroid cells from patients with autoimmune thyroid di sease:study of thyroid xenografts in nude and severe combined immu nodeficient mice and treatment with FK-506[J].J Clin End ocrinol Metab,1995,80:3724.
[8]Ishikawa N.Expression of adhesion molecules on infiltrating T cells in thyroid glands from patients with Graves' disease.C linEx p Immunol,1993,94:363.
[9]Marazuela M.Adhesion molecules from the LFA-1/ ICAM-1,3 and VLA-4/ VCAM-1 pathways on Tlymphocytes andvascular endo th elium in Graves ' and Hashimoto' s thyroidglands[J].Eur J I mmunol,1994,24:2483.
[10]Balazs C,Kiss E.Soluble intercellular adhesion molecule-1(s ICAM-1) in Graves' disease[J].Acta Microbiol Immunol Hung,1994,41:451-456.
[11]张丽,王德风,王德全.国外医学内分泌学分册,1999,(2):15-16.
[12]Metcalfe RA,Tandon N,Tamatani T,et al.Adhesion molecule mao no Clonal Antibodies inhibit experimental autoimmune thyroiditi s[J].Immunology,1993,80:493-497.
[1]Sen R Baltinore D.Muliple nuclear factors interact with the inmunoglobulin enhancer sequence cell[J].1986,46(5):705.
[2]Grey ST,Arvelo MB,Hasenkamp W,Bach FH,Ferran C.A20inhibits cytokine-induced apoptosis and nuclear factor kappaB-dependent geneactivation in islets[J].J Exp Med,1999,190(8):1135-1146.
[3]Jue DM,Jeon KI,Jeong JY Nuclear factor kappaB(NF-kappaB)pathway as a therapeutic target in rheumatoid arthritis [J].J Korean Med Scil999,14(3):231-238.
[4]Hilliard B,Samoilova EB,Liu TS,Rostami A,Chen Y Experimental autoimmune encephalomyelitis in NF-kappa B-deficient mice:roles of NF-kappa B in the activation and differentiation of autoreactive T cells[J].Jimmunol,1999,163(5):2937-2943.
[5]Burgos P,Metz C,Bull P,Pincheira R,Massardo L,Errazuriz C,Bono MR,Jacobelli S,Gonzalez A.Increased expression of c-rel,from the NF-kappaB/Rel family,in T cells from patients with systemic lupusery thematosus.J Rheumatol 2000,27(1):116-27.
[6]Altavilla D,Saitta A,Squadrito G,et al.Evidence for a role of nuclear factor2kappa B in acute hypovolemic hemorrhagic shock.[J].Surgery,2002,131:50-8.
[7]Altavilla D,Saitta A,Guarini S,et al.Oxidatice stress causes nu2clear factor2kappa B activation in acute hypovolemic hemorrhagicshock[J].Free Radic BiolMed,2001,30:1055-1066.
[8]GroveM,PlumbM.C/EBP,NF2kappa B,and c2Ets familymembers and transcriptional regulation of the cell2specific and induciblemacrophage inflammatory protein 1 alpha immediate[J].Mol CellBiol,1993,13:5276-5289.
[9]夏丽娟,陈飞虎.核因子-κB的分子生物学特性及其在炎性分子反应的作用[J].安徽医药,2005,9(3):162-164.
[10]闵迅,陈代雄,王永伦等.NF-κB在Graves病免疫病理机制中的意义[J].中国病理生理杂志,2009,25(3):536-540.
[11]赵建东、王延君、孔维佳.核因子-κB及ICAM-1 mRNA在变应性鼻炎鼻黏膜中的表达[J].临床耳鼻咽喉头颈外科杂志,2008,22(2):57-60.
[1]程磊,刘继祥.血清IL-2和IL-6及TNF-α检测在甲亢病中的临床应用[J].现代医药卫生,2005,21:3288.
[2]Bartalena L,Brogioni S,Grasso L,Mart ino E.Interleukin-6And thvroid[J].Eur J Enaocrinol,1995,132(4):386-393.
[3]Corrales JJ,Orfao A,Lopez A,et al.Analysis of IL-2 and IL-6binding to peripheral blood lymphocytes in Graves disease:relationship with disease activity[J].Cytometry,1997,15:30(3):118-123.
[4]Simons PJ,Delemarre F6,Drexhage HA.Antigen-presenting dendritic cell sas regulators of the growth of thyrocytes:a role of interleukin-1 beta and interleukin-6[J].Endocrinology,1998,139(7):3148-3156.
[5]Gi rvent M,Maestro S,Hernandez R,et al.Euthyroid Sick syndrome.a ssociated endocrine abnormalities.and outcome in elderly patient s undergoing emergencyoperation[J].Surgery,1998May,123(5):560-567.
[6]Aust G,Schbaum WA.Expression of cytokines in the thyroida hyrocytes as potentent iaicytokineproducers[J].Exp C1 in endo crin Diabetes,1996;104:46-50.
[7]Wat son PF,Pickerill AP,Davies et al.Semi-quantitative analysi-s of interleukin-1 alpha.interleukin-6 and interleukin -smRNA expres sion human thyrocytes[J].J M01 Endocrinol.1995,15(1):11-21.
[8]Yamazaki K,Yamada E,Kanaji Y,et al.Interleukin-6(IL-)inhibit Sthyroidfunction in 1,he plesence of soluble 1L-6 receptor in cultured human thyroid foilicles[J].Endocrinology,1996,137(11):4857-4863.
[9]张致丹.Graves病患者血清IL-6和IFN含量变化与临床意义[J].中国误诊学杂志,2009,9(7):1535.
[10]哈丽亚·哈力木别克,茹仙古丽·吾买尔,巴雅.Graves病患者血清IL-2、IL-6及TNF的变化[J].中国误诊学杂志,2009,9(6):1303-1304.
[11]王小宁,余江毅,顾志峰.温肾方对EAT模型甲状腺组织IL-6β表达影响的实验研究[J].江苏中医药2005,26(12):59-61.
[12]董吉祥,谢莹,汪寅,等.Graves病患者外周血IL-6.TNF-水平表达的变化及意义[J].中国免疫学杂志2006,(22):378-380.
[13]李宏.儿童AITD患者血清IL-12、IL-10在疾病不同阶段的观察[D].天津医科大学,2006
[14]Onstant SL-Bottomlv L induction of,Th_1 and Th_2 CO_4~+T Cell response the alternative approaches[J]Ann lieⅡ Immunol.1997,15,297-322.
[15]Xu WD,Fireste in GS,Taetle R,et al Cytokines in chronic in flammatory arthritis Ⅱ,granu locytes-macrophage colony stim ulating factor in rheum atoid synovial effusions[J].J G in In vest,1989,83:876-882.
[16]Takeoka K,Watanabe M,Mat suzuka F,et al.Increase of seru m interleukin-10 in intractable Graves disease[J].Thyroid.2004Mar 14(3):201-205.
[17]Wat son PF,Pickeri 11 AP,Davies R,et al.Analysis of cytokine gene expression in Graves' disease and multinodular goiter[J].J Clin Endocrinol Metab.1994 Aug,79(2):355～360.
[18]Al-Humaidi MA.SeI.um cytokines levels in Graves,disease.J Saudi Med[J].2000,21(7):539～644.
[1]Jones B M,kwok C C,Kung AW.Effect of radioact ive iodine therapy on eytokine production in Graves disease;transient increase in IL-4 IL-6 IL-10 and tumor necreasees in interferor gamma production [J].J Clin Endocrionlm Metab,1999,84(11):4106.
[2]Salvi M,pedrazzoni M,Girasole G,et al Serum concentra tions of proinflammatory cytokines in Graves'disease effect of treatment thyroid function ophthaln opathy and cigarette smokin g[J].Eur Endor crino J 2000,143(2):197-202.
[3]Liao YF,Wang BJ,Cheng HT,Kuo LH,Wolfe MS.Tumor necrosis factor-alpha,interleukin-lbeta,and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway[J].J.Biol.Chem.2004;279(47),49523-49532.
[4]Zhen Q H,Ahney E R Detection of vivo productin of turner Necros is factor alpha hY human thyroid epithelial cells [J]lmmunology,1992,75:456-462.
[5]段宇.甲状腺组织表达细胞因子IL-6 TNF-α mRNA基因的研究[J]南京医利大学学报,2000,20:91-93.
[6]Eugenin EA,Branes MC,Berman JW,Saez JC.TNF-αlpha plus IFN-gamma induce connexin43 expression and formation of gap junctions between human monocytes/macrophages that enhance physiological responses[J].J.Immunol.2003;170(3),1320-1328.
[1]白耀,主编.甲状腺病学—基础与临床[M].北京:科技技术文献出版社,2003,146.
[2]张木勋,吴亚群[M].甲状腺疾病诊疗学[M].北京:中国医药科技出版社2006,191-192.
[3]刘泽林.王玉磷.李路.等.Graves病患者血中细胞因子的变化[J].暨南大学学报,2007,28(2):176-178.
[4]Wakelknnp M,Gerdngn N van derM eerjW,et al Both Th_1 and Th_2-derived cvtok ines in Serum are elevated in Graves ophthalmopathyl[J].Clinexp lnmunol 2000,121(3):453-457.
[5]廖二元,超楚生.内分泌学[M].北京:人民卫生出版社,2001,664-693.
[6]倪晓燕.HLA等位基因多态性与自身免疫性甲状腺病[J].《国外医学》内分泌学分册,1998,18(3):113-116.
[7]Ishikawa N.Expression of adhesion molecules on infiltrating Tcells in thyroid glands from patients with Graves' disease[J].ClinExp Immunol,1993,94:363.
[8]OPAL S M.WHERRY J C.GRINT P.Interleukin-10;potential benefits and possible risk in clinical infection diseases[J].Clin Infect Dis.1998,27(6):1495-1507.
[9]BOGDAN C,PAIK J,VODOVOTZ Y.et al.Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10[J].J Biol CHEN,1992,267(32):301-308.
[10]RONCAROLO M G.BACCHETA R.BORDIGNON C,et al.Type 1 T-regulatory cells[J].Immunol Rev,2001,182:68-79.
[11]JENKINS JK,MALYAKM,ARENDWP.The effects of interleukin-10on interleukin-1 receptor antagonist and interleul:in-1 beta production in human monocytes and neutrophils[J].Lymphokine Cytokine Res,1994,13(1);47-54.
[12]钟永亮,唐荣德,肝主疏泄与甲亢病机关系初探[J].湖南中医学院学报,1994,14(3):14-16.
[13]张安玲,肝火的形成致病机制及证治规律探微[J].中医药学刊,2002,20(1):70-71.
[14]居建英,居建玲,试论肝火证[J].天津中医学院学报,2002,19(4):6.
[15]崔向阳。中医肝火证与A型性格关系探讨[J].空军总医院学报。1989.5(3):154～155.
[16]蒋岩,尹建豪.夏枯草对动物胸腺、脾脏和肾上腺的影响[J].甘肃医药,1988,7(4):4.
[17]郑昱,乔成栋,苑伟等.夏枯草胶囊对溃疡性结肠炎大鼠外周血T 淋巴细胞亚群表达的影响[J].中国中西医结合消化杂志,2004,12(1):10.
[18]马德恩,王竹梅.夏枯草的抗炎作用及对免疫器官影响的研究[J].山西医药杂志,1983,3(2):51-52.
[19]杨坤.夏枯草口服液在不同甲状腺功能状态甲状腺肿大患者中的应用[J].中国中西医结合杂志2007,27(1):37-39.
[20]王钢力,陈德帽,赵淑杰.栀子属植物化学成分研究进展[J].中国中药杂志.1996,21(2):67-67.
[21]姚全胜,周国林,朱延勤等.栀子抗炎、治疗软组织损伤有效部位的筛选研究[J].中国中药杂志,1991,16(8):486-486.
[22]Kimura Y,et al.J Elhnoyharrnacol,1997,57(1):63.
[23]蔡仙德、穆维同.黄芩苷对小鼠细胞免疫功能的影响[J].南京铁道医学院学报,1994,13(2):65-68.
[24]王新慧,蔡仙德.黄芩苷对小鼠细胞免疫粘附功能的促进作用[J].中国实验临床免疫学杂志.1992,4(3):41-43.
[25]中华本草[M].上海科技出版社.1999,218.
[26]何金森.甲亢虚火旺证与气阴两虚证的初步探讨[J].1983,14(9):67.
[27]Meyerson LR et al.Neurochesn.Ras 1978,11:239.
1.李富生主编.常见病中医临床治疗进展[M].中国中医药出版社.1991.
2.王洪泉,徐灿冲,王蕾.程益春教授治疗甲亢临证经验选粹[J].2007,17(3)162.
3.姜家全,徐灿坤,韩吉淼 辨证治疗甲状腺功能亢进症的思路与方法[J].实用中医内科杂志,2003,17(6):279.
4.陈继东,程健高.甲状腺机能亢进症从肝论治辨析[J].湖北中医杂志,2007,29(2):18.
5.杨庆云.甲亢中医治疗近况[J].四川中医.1988,(8):44.
6.王开云.安徽中医临床杂志[J].2000,12(3):182.
7.简任佑.甲状腺功能亢进症中医辨证的初步研究[D].广州中医药大学.2002.
8.安平,梁雪.毒性弥漫性甲状腺肿研究进展[J].中医药信息,2001,21(4):17-19.
9.郑献敏.甲亢(瘿气)临床辨证分型规律的研究[D].广州中医药大学.2006.
10.郭宝荣,冯建华,张娟.愈瘿片治疗甲状腺功能亢进症的临床研究[J].山东中医药大学学报,2000,24(2):97-100.
11.向楠,周亚娜.从毒论治甲状腺机能亢进症[J].湖北中医杂志,2005.27(6):5-8.
12.郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002,226-233.
13.曹国蓉.甲状腺机能亢进症的辩证论治[J].中医杂志,1996,(6):5.
14.李景顺.浅谈中医对甲亢的辨证施治[J].辽宁中医杂志,1981,(3):28.
15.金舒白.针灸治疗甲状腺机能亢进症的经验介绍[J].中国针灸,1982,(1):14.
16.陈建军.甲状腺机能亢进症的中医分型探论.全国第四届中医甲状腺疾病学术会议论文集.
17 余惠民.从肝论治甲状腺机能亢进症[J].广西中医药,1986,(5):23.
18.杨树先,王延山.甲亢的中医辨证施治[J].中国社区医师杂志,2001,12(12):27.
19.成肇智,刘琼,傅蔷.毒性弥漫性甲状腺肿分期辨治[J].中医药通报,2003,2(2):67-68.
20.张志荭,张传平.疏肝消瘿汤治疗甲状腺功能亢进32例[J].实用中医药杂志,2001,17(9):26.
21.洪志豪.夏玄平肝汤治疗甲状腺机能亢进24例[J].四川中医,2000,18(7):19.
22.赵文学.玉液汤治疗甲亢42例[J].北京中医,1999,24(6):24.
23.李以稳.中西医结合治疗甲亢58例疗效观察.江苏中医2005,(5):17.
24.王科成,刘冬岩,贾义呈,等.三黄抑亢胶囊辅以小剂量他巴唑治疗Graves病的疗效观察[J].中医杂志,1999,40(5):290.
25.杨洪,胡建兵,任卫东中药甲亢舒与131Ⅰ联合治疗甲亢临床观察[J].实用中西医结合临床,2003,3(2):13.
26.龙炎.中西医结合治疗甲状腺机能亢进症50例疗效观察[J].湖南中医药导报,2001,7(9):458.
27.林兰,李鸣摘,刘喜明,等.中药甲亢宁治疗阴虚阳亢型甲状腺功能亢进症的临床研究[J].中国中西医结合杂志,1999,19(3):144-146.
28.梁九根,蒋宁一,吕斌,等.甲亢舒配合~(131)碘治疗甲状腺机能亢进症的临床观察[J].中国中西医结合杂志,2000,20(10):774-774.
29.陈如泉主编.甲状腺疾病中西医诊断与治疗.[M].北京:中国医药科技出版社,2001
30.王立琴,陈金锭,张其兰.外敷消瘿膏治疗甲状腺肿临床观察及实验初步研究[J].中医杂志,1993,34(3):153.
31.黄柳和.挑筋割脂埋线疗法治疗甲亢[J].中国针灸,1995,28(1).
32.孙克兴,庞烟,魏建子,等.针药结合治疗Graves病眼征的临床观察[J].上海针灸杂志,2000,19(3):5.